Northwest Biotherapeutics, Inc. (NWBO) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Northwest Biotherapeutics, Inc. (NWBO) trades at $0.1715 with AI Score 43/100 (Grade C). Northwest Biotherapeutics, Inc. is a biotechnology company focused on developing personalized immune therapies for cancer. Market cap: $282M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for NWBO: NWBO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NWBO against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
NWBO: this read rests on a single discipline (MoonshotScore) — the other council disciplines have no scored data yet.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Northwest Biotherapeutics, Inc. (NWBO) Healthcare & Pipeline Overview
Northwest Biotherapeutics, Inc. is a biotechnology firm specializing in personalized cancer immunotherapies using its DCVax platform. Their lead candidate, DCVax-L, targets Glioblastoma multiforme, a significant unmet need in oncology. The company operates in the competitive biotechnology sector, focusing on innovative approaches to cancer treatment.
What Is the Investment Thesis for NWBO?
Northwest Biotherapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's lead product, DCVax-L, targeting Glioblastoma multiforme, has completed Phase III trials, representing a potential near-term catalyst. Successful commercialization of DCVax-L could drive significant revenue growth. However, the company's negative profit margin of -9609.2% and reliance on a single platform technology represent significant risks. The company's beta of -0.83 suggests a degree of inverse correlation with the market, but this may be due to its unique developmental stage. Investors should closely monitor regulatory approvals, commercialization strategies, and future clinical trial results. The company's ability to secure partnerships and funding will be crucial for long-term success.
Based on FMP financials and quantitative analysis
NWBO Key Highlights
DCVax-L has completed Phase III clinical trials for Glioblastoma multiforme brain cancer, representing a potential near-term catalyst.
- Gross margin of 44.4% indicates potential for profitability upon commercialization of its products.
- The company is developing DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors, expanding its pipeline.
- Market capitalization of $282M reflects investor valuation of its technology and pipeline.
- The company's P/E ratio is -3.65, reflecting current losses but potential future earnings.
Who Are NWBO's Competitors?
NWBO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AVCTF Avacta Group Plc | $0.90 | -10.00% | $422M | 47 |
| CLVLY Clinuvel Pharmaceuticals Limited | $6.74 | +0.97% | $340M | 50 |
| CMVLF Cellectis S.A. | $3.47 | +12.66% | $252M | 51 |
| CYDY CytoDyn Inc. | $0.21 | +3.26% | $282M | 47 |
| FGHQF Frontage Holdings Corporation | $0.15 | +0.00% | $304M | 42 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NWBO's Key Strengths?
Proprietary DCVax platform technology.
- Personalized approach to cancer immunotherapy.
- Completed Phase III clinical trials for DCVax-L.
- Experienced management team.
What Are NWBO's Weaknesses?
Negative profit margin.
- Reliance on a single platform technology.
- Limited financial resources.
- Dependence on regulatory approvals.
What Could Drive NWBO Stock Higher?
Potential regulatory approval of DCVax-L for Glioblastoma multiforme.
- Phase I/II clinical trial results for DCVax-Direct in inoperable solid tumors.
- Strategic partnerships and collaborations with pharmaceutical companies.
- Expansion into new geographic markets.
- Advancements in the DCVax platform technology.
What Are the Key Risks for NWBO?
Financial-distress signal — its Altman Z-Score of -30.10 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Regulatory delays or rejection of DCVax-L.
- Clinical trial failures for DCVax-Direct.
- Competition from larger pharmaceutical companies.
- Difficulty in securing funding.
- Limited liquidity due to OTC market trading.
What Are the Growth Opportunities for NWBO?
- Commercialization of DCVax-L: The successful commercialization of DCVax-L for Glioblastoma multiforme represents a significant growth opportunity. Securing regulatory approvals and establishing effective manufacturing and distribution channels are crucial for capturing market share. This opportunity is near-term, contingent on regulatory decisions expected within the next 12-18 months.
- Expansion of DCVax-Direct: The ongoing Phase I/II clinical trials for DCVax-Direct in inoperable solid tumors offer a longer-term growth opportunity. Positive trial results could lead to the expansion of DCVax technology to treat a broader range of cancers. The market for solid tumor therapies is substantial, representing a multi-billion dollar opportunity. This expansion is contingent on clinical trial success over the next 2-3 years.
- Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies could accelerate the development and commercialization of DCVax therapies. Collaborations could provide access to additional funding, expertise, and distribution networks. This represents an ongoing opportunity to enhance the company's resources and capabilities.
- Geographic Expansion: Expanding into new geographic markets, particularly in Europe and Asia, could drive revenue growth. Establishing regulatory pathways and distribution channels in these regions will be essential. This represents a medium-term opportunity, with potential expansion over the next 3-5 years.
- Advancements in DCVax Platform: Continued innovation and improvements to the DCVax platform could lead to the development of new and more effective cancer therapies. This includes exploring new targets and optimizing the delivery and activation of dendritic cells. This represents an ongoing opportunity to maintain a competitive edge and expand the applications of the DCVax technology.
What Are NWBO's Competitive Advantages?
- Proprietary DCVax platform technology.
- Personalized approach to cancer immunotherapy.
- Completed Phase III clinical trials for DCVax-L.
- Experienced management team in biotechnology and oncology.
What Does NWBO Do?
Northwest Biotherapeutics, Inc., founded in 1996 and headquartered in Bethesda, Maryland, is a biotechnology company dedicated to developing personalized immune therapies for cancer. The company's core technology, DCVax, utilizes activated dendritic cells to stimulate a patient's immune system to target and attack cancer cells. Their lead product, DCVax-L, has completed Phase III clinical trials for the treatment of Glioblastoma multiforme (GBM), an aggressive form of brain cancer. DCVax-L represents a personalized approach, using the patient's own dendritic cells to create a targeted immunotherapy. In addition to DCVax-L, Northwest Biotherapeutics is developing DCVax-Direct, which is currently in Phase I/II clinical trials for the treatment of inoperable solid tumors. This therapy aims to address a broader range of cancers by directly injecting activated dendritic cells into the tumor site. The company operates both in the United States and internationally, seeking to bring its innovative cancer therapies to patients worldwide. With a focus on personalized medicine and immune-based approaches, Northwest Biotherapeutics aims to improve outcomes for cancer patients facing limited treatment options.
What Products and Services Does NWBO Offer?
- Develop personalized immune therapies for cancer.
- Utilize the DCVax platform technology to activate a patient's own immune system.
- Target Glioblastoma multiforme brain cancer with DCVax-L.
- Conduct Phase I/II clinical trials for DCVax-Direct to treat inoperable solid tumors.
- Research and develop new applications for the DCVax platform.
- Manufacture and distribute personalized cancer therapies.
How Does NWBO Make Money?
- Develop and commercialize personalized cancer immunotherapies.
- Generate revenue through the sale of DCVax-L and future DCVax products.
- Seek partnerships and collaborations to fund development and commercialization efforts.
- Obtain grants and government funding for research and development.
What Industry Does NWBO Operate In?
Northwest Biotherapeutics operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory hurdles. The market for cancer therapies is substantial and growing, driven by an aging population and increasing cancer incidence rates. Personalized immunotherapies, like DCVax, represent a growing trend in cancer treatment, offering the potential for more targeted and effective therapies. The company competes with larger pharmaceutical companies and other biotechnology firms developing novel cancer treatments. Success in this industry requires strong scientific expertise, successful clinical trials, and effective commercialization strategies.
Who Are NWBO's Key Customers?
- Cancer patients with Glioblastoma multiforme.
- Hospitals and cancer treatment centers.
- Oncologists and other healthcare professionals.
- Potential partners in the pharmaceutical industry.
Forward Outlook
Wall Street analysts project Northwest Biotherapeutics, Inc. revenue of about $1.6M for fiscal 2026, with EPS near $-0.05.
Financial Health
Northwest Biotherapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -30.10 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Northwest Biotherapeutics, Inc. stands at 62.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -54.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -15.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.07 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -14.7%, the inverse of the P/E and a quick read on earnings relative to price.
Northwest Biotherapeutics, Inc. (NWBO) Valuation Context
Valued at $282M, NWBO is classified as a micro-cap stock. Relative to its peer group, NWBO's quantitative score of 43/100 is roughly in line with the peer average of 47/100.
Company Profile
Northwest Biotherapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Bethesda, US. The company is led by CEO Linda F. Powers. NWBO has traded publicly since 2001.
NWBO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Market sentiment data being refreshed
- Community discussions being analyzed
Bear Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Risk factors being evaluated
- Market concerns being processed
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NWBO Latest News
No recent news available for NWBO.
NWBO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NWBO.
Price Targets
Wall Street price target analysis for NWBO.
NWBO MoonshotScore
What does this score mean?
The MoonshotScore rates NWBO 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Linda F. Powers
CEO
Linda F. Powers has extensive experience in the biotechnology and finance industries. Her background includes founding and managing venture capital firms focused on healthcare investments. She has served on the boards of numerous biotechnology companies and has a track record of guiding companies through clinical development and commercialization. Her expertise spans corporate finance, strategic planning, and business development within the life sciences sector.
Track Record: Under Linda Powers' leadership, Northwest Biotherapeutics has advanced DCVax-L through Phase III clinical trials for Glioblastoma multiforme. She has overseen the development of the DCVax-Direct program and has been instrumental in securing funding for the company's research and development efforts. Her strategic decisions have focused on advancing the DCVax platform and expanding its potential applications.
NWBO OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Northwest Biotherapeutics may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies on this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance compared to companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with higher risk profiles.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Potential for price manipulation and fraud.
- Higher risk of delisting or trading suspension.
- Limited liquidity and wider bid-ask spreads.
- Greater volatility compared to major exchanges.
- Verify the company's financial statements and disclosures.
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory filings and compliance.
- Monitor trading volume and bid-ask spreads.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Completion of Phase III clinical trials for DCVax-L.
- Development of the DCVax-Direct program.
- Experienced management team with a background in biotechnology.
- Focus on personalized cancer immunotherapies.
- Operation in the biotechnology sector.
NWBO Healthcare Stock FAQ
What does the AI Score mean for NWBO?
NWBO holds an AI Score of 43/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Northwest Biotherapeutics, Inc. is a biotechnology company focused on developing personalized immune therapies for cancer. Their lead product, DCVax-L, targets Glioblastoma multiforme brain cancer …
What does Northwest Biotherapeutics, Inc. do?
Northwest Biotherapeutics, Inc. is a biotechnology company that develops personalized immune therapies for cancer. The company's core technology, DCVax, uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Their lead product, DCVax-L, has completed Phase III clinical trials for the treatment of Glioblastoma multiforme, an aggressive form of brain cancer. They are also developing DCVax-Direct for inoperable solid tumors.
What are the main risks for NWBO?
The main risks for Northwest Biotherapeutics include the potential for regulatory delays or rejection of DCVax-L, clinical trial failures for DCVax-Direct, competition from larger pharmaceutical companies, and difficulty in securing funding. As an OTC-traded company, NWBO also faces risks related to limited liquidity and potential volatility. Investors should carefully consider these factors before investing.
What is Northwest Biotherapeutics, Inc.'s drug pipeline status?
Northwest Biotherapeutics' pipeline is centered around its DCVax platform. The lead product, DCVax-L, has completed Phase III clinical trials for Glioblastoma multiforme. DCVax-Direct is currently in Phase I/II clinical trials for inoperable solid tumors. The company is focused on expanding the applications of its DCVax technology to treat a broader range of cancers. Upcoming catalysts include potential regulatory decisions for DCVax-L and clinical trial results for DCVax-Direct.
What revenue streams does Northwest Biotherapeutics, Inc. have in healthcare?
Currently, Northwest Biotherapeutics does not have established revenue streams as it awaits regulatory approval for its lead product, DCVax-L. Future revenue streams are anticipated to be generated through the sale of DCVax-L for Glioblastoma multiforme and potential future DCVax products for other cancer types. Revenue will depend on successful commercialization, market penetration, and geographic expansion. The company may also generate revenue through partnerships and collaborations with pharmaceutical companies.
What are the key factors to evaluate for NWBO?
Northwest Biotherapeutics, Inc. (NWBO) holds an AI score of 43/100 (low). Northwest Biotherapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does NWBO data refresh on this page?
NWBO's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NWBO's recent stock price performance?
Northwest Biotherapeutics, Inc. (NWBO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary DCVax platform technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NWBO overvalued or undervalued right now?
Northwest Biotherapeutics, Inc. (NWBO) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited due to the company's OTC status and lack of recent filings.
- AI analysis is pending, limiting the depth of insights.
- The biotechnology industry is inherently risky, and clinical trial outcomes are uncertain.